🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Yimiao Zhang

Jiangsu University

ORCID: 0009-0009-9572-3079

Also affiliated with Beijing Institute of Technology, Peking University, Peking University First Hospital, Shandong First Medical University, Nanjing University of Aeronautics and Astronautics

MedicineMaterials ScienceEngineering

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Type II Glycoengineered Anti-CD20 Antibody MIL62 or Cyclosporine in Chinese Primary Membranous Nephropathy: A Multicenter, Randomized, Open-Label Phase 1b/2 Trial”.

Type II Glycoengineered Anti-CD20 Antibody MIL62 or Cyclosporine in Chinese Primary Membranous Nephropathy: A Multicenter, Randomized, Open-Label Phase 1b/2 Trial

Journal of the American Society of Nephrology(2024)10.1681/asn.2024yaqz098x
N/A
0DataRank · unranked
0 citations

Alexandra P. Lewis, Hua Zhou, Hong Li Lin, Guangqun Xing, Wei Chen +22 more

The Type II Glycoengineered Anti-CD20 Antibody MIL62 or Cyclosporine in Chinese Primary Membranous Nephropathy: Updated Results of an Ongoing, Multicenter, Randomized, Open-Label Phase 1b/2 Trial

Journal of the American Society of Nephrology(2023)10.1681/asn.20233411s1988a
N/A
0DataRank · unranked
0 citations

Zhao Cui, Alexandra P. Lewis, Hua Zhou, Hong L. Lin, Guangqun Xing +23 more

#3776 THE TYPE Ⅱ ANTI-CD20 MONOCLONAL ANTIBODY MIL62 OR CYCLOSPORINE IN CHINESE PRIMARY MEMBRANOUS NEPHROPATHY: PRELIMINARY RESULTS OF A PHASE ⅠB/Ⅱ TRIAL

Nephrology Dialysis Transplantation(2023)10.1093/ndt/gfad063c_3776
N/A
0DataRank · unranked
0 citations

Yimiao Zhang, Alexandra P. Lewis, Hua Zhou, Hongli Lin, Guangqun Xing +21 more